International Isotopes acquires remaining 75% of RadQual for $4.4M in stock; expects immediate accretion

RADNOSTIX INC

Acquired remaining 75% of RadQual for $4.4M, paying 40,176,236 shares at $0.11/share based on 60-day VWAP.
RadQual is a premier developer of nuclear medicine QC products; INIS had been contract manufacturer and manager since 2017.
Transaction expected to immediately increase shareholder equity, improve net profit margin, and be accretive.
RadQual launched several new products in 2021 including Symbia source, D-SPECT line source, and germanium rods.
At annual meeting, shareholders elected Laflin, Grosso, and Atcher as directors; ratified Haynie & Company as auditor.

item 1.01 item 2.01 item 3.02 item 5.07 item 7.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.